Sanofi reported Q3 2024 sales growth of 15.7%, reaching 13.4 billion euros ($14.2 billion), with EPS up 12.2% to 2.86 euros.

The French government has taken a small stake in Sanofi's consumer healthcare business Opella, following political backlash ...

Sanofi  (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, ...

Leerink Partners analyst David Risinger has maintained their bullish stance on SNYNF stock, giving a Buy rating yesterday. David Risinger has ...

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% ...

A stake by France-owned Bpifrance and promise of local job retention have allayed political backlash over the sale of ...

French pharmaceutical company Sanofi confirmed on Monday its plans to sell a controlling stake in its consumer health ...

Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ...

In a report released today, Peter Welford from Jefferies maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target ...

Head of Investor Relations Welcome to the Q3 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide number 3. Here we have the usual ...

This week, Roche RHHBY announced its third-quarter and nine-month results. Sanofi SNY confirmed that it is holding exclusive ...

and packaging of Sanofi’s SoloStar insulin pens and advanced insulin products. This strategic partnership reinforces our ...